AKT1 and neoplasm: To investigate the role of Akt isoforms in tumor cell chemoresistance and its use as a preclinical model for new treatments, we treated mice with 6 rounds of the NCCN-indicated PCa treatment, taxane, along with low doses of Akt inhibitors, including PI3Ki, pan-Akti, Akt1i, and Akt2i (all 5 mg/kg body weight), or equal amounts of dimethyl sulfoxide injected as controls (Figure 4D).